Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nastech Nascobal intranasal gel achieves higher maintenance B12 levels than injectable vitamin therapy.

Executive Summary

NASTECH NASCOBAL ACHIEVES HIGHER B12 LEVELS THAN INJECTABLE VITAMIN DOSE in a pharmacokinetic study supporting the approval of the intranasal vitamin B12 gel. Nascobal 500 mcg "resulted in a consistent increase in pre-dose serum B12 levels during one month of [weekly] treatment[s] above that seen one month after 100 mcg intramuscular dose," labeling states.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029223

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel